Neurizon Therapeutics Limited
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Neurizon Files IND Application to Support HEALEY ALS Platform Trial 2024-12-18 10:59
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study 2024-11-19 20:30
Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe 2024-11-11 20:30
PharmAust affirms corporate strategy with name change to Neurizon Therapeutics 2024-10-16 04:14
1